Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enoxaparin Versus Unfractionated Heparin in PCI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00439855
Recruitment Status : Completed
First Posted : February 26, 2007
Last Update Posted : February 26, 2007
Sponsor:
Information provided by:
Triemli Hospital

Brief Summary:
Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Enoxaparin i.v. Drug: unfractionated heparin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 2100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enoxaparin Versus Unfractionated Heparin in PCI
Study Start Date : September 2003
Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners




Primary Outcome Measures :
  1. Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary Outcome Measures :
  1. major bleeding, minor bleeding, thrombocytopenia


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PCI for stable ischemia or ACS

Exclusion Criteria:

  • Cardiogenic shock,
  • Pretreatment with study drugs,
  • Lack of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00439855


Locations
Layout table for location information
Switzerland
Division of Cardiology Triemli Hospital Zurich
Zurich, Switzerland, 8063
Sponsors and Collaborators
Triemli Hospital
Investigators
Layout table for investigator information
Principal Investigator: osmund bertel, MD Division of Cardiology Triemli Hospital Zurich

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00439855     History of Changes
Other Study ID Numbers: ZEUS
First Posted: February 26, 2007    Key Record Dates
Last Update Posted: February 26, 2007
Last Verified: February 2007
Keywords provided by Triemli Hospital:
Enoxaparin, heparin, hemorrhages
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Heparin
Calcium heparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action